These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 15358619)

  • 41. Physician Education: The Erythropoietin Receptor and Signal Transduction.
    Yoshimura A; Arai K
    Oncologist; 1996; 1(5):337-339. PubMed ID: 10388012
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Protein tyrosine phosphatase 1B participates in the down-regulation of erythropoietin receptor signalling.
    Cohen J; Oren-Young L; Klingmuller U; Neumann D
    Biochem J; 2004 Jan; 377(Pt 2):517-24. PubMed ID: 14527337
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lovastatin suppresses erythropoietin receptor surface expression through dual inhibition of glycosylation and geranylgeranylation.
    Hamadmad SN; Hohl RJ
    Biochem Pharmacol; 2007 Aug; 74(4):590-600. PubMed ID: 17586475
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Calmodulin physically interacts with the erythropoietin receptor and enhances Jak2-mediated signaling.
    Kakihana K; Yamamoto M; Iiyama M; Miura O
    Biochem Biophys Res Commun; 2005 Sep; 335(2):424-31. PubMed ID: 16084495
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A minimal cytoplasmic subdomain of the erythropoietin receptor mediates p70 S6 kinase phosphorylation.
    Zhang MY; Barber DL; Alessi DR; Bell LL; Stine C; Nguyen MH; Beattie BK; Cheung JY; Miller BA
    Exp Hematol; 2001 Apr; 29(4):432-40. PubMed ID: 11301183
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification of a cytoplasmic motif in the erythropoietin receptor required for receptor internalization.
    Levin I; Cohen J; Supino-Rosin L; Yoshimura A; Watowich SS; Neumann D
    FEBS Lett; 1998 May; 427(2):164-70. PubMed ID: 9607304
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Up-regulated endogenous erythropoietin/erythropoietin receptor system and exogenous erythropoietin rescue retinal ganglion cells after chronic ocular hypertension.
    Fu QL; Wu W; Wang H; Li X; Lee VW; So KF
    Cell Mol Neurobiol; 2008 Feb; 28(2):317-29. PubMed ID: 17554621
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Erythropoietin Receptor Structural Domains.
    Li Q; Kang C
    Vitam Horm; 2017; 105():1-17. PubMed ID: 28629512
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Low doses of EPO activate MAP kinases but not JAK2-STAT5 in rat vascular smooth muscle cells.
    Ammarguellat F; Llovera M; Kelly PA; Goffin V
    Biochem Biophys Res Commun; 2001 Jun; 284(4):1031-8. PubMed ID: 11409898
    [TBL] [Abstract][Full Text] [Related]  

  • 50. N-glycosylation-defective receptor for erythropoietin can transduce the ligand-induced cell proliferation signal.
    Nagao M; Morishita E; Hanai Y; Kobayashi K; Sasaki R
    FEBS Lett; 1995 Oct; 373(3):225-8. PubMed ID: 7589471
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeted near-infrared imaging of the erythropoietin receptor in human lung cancer xenografts.
    Doleschel D; Mundigl O; Wessner A; Gremse F; Bachmann J; Rodriguez A; Klingmüller U; Jarsch M; Kiessling F; Lederle W
    J Nucl Med; 2012 Feb; 53(2):304-11. PubMed ID: 22228796
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Insertion of an NPVY sequence into the cytosolic domain of the erythropoietin receptor selectively affects erythropoietin-mediated signalling and function.
    Liron T; Nahari T; Souroujon MC; Neumann D
    Biochem J; 2010 Mar; 427(2):305-12. PubMed ID: 20136632
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Erythropoietin and its receptor in breast cancer: putting together the pieces of the puzzle.
    Mannello F; Tonti GA
    Oncologist; 2008 Jul; 13(7):761-8. PubMed ID: 18596367
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Downregulation of erythropoietin receptor by overexpression of phospholipase C-gamma 1 is critical for decrease on focal adhesion in transformed cells.
    Kang JK; Chang CH; Nam HJ; Kim SK; Ahn KJ; Seok H; Park SJ; Kang YJ; Jo YS; Shong M; Kim H
    Cell Oncol (Dordr); 2011 Feb; 34(1):11-21. PubMed ID: 21360263
    [TBL] [Abstract][Full Text] [Related]  

  • 55. SH2-Containing protein tyrosine phosphatase-1 (SHP-1) association with Jak2 in UT-7/Epo cells.
    Wu DW; Stark KC; Dunnington D; Dillon SB; Yi T; Jones C; Pelus LM
    Blood Cells Mol Dis; 2000 Feb; 26(1):15-24. PubMed ID: 10772872
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma.
    Mohyeldin A; Lu H; Dalgard C; Lai SY; Cohen N; Acs G; Verma A
    Neoplasia; 2005 May; 7(5):537-43. PubMed ID: 15967106
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Role of Erythropoietin in Cerebral Glioma: An Innovative Target in Neuro-Oncology.
    Torregrossa F; Aguennouz M; La Torre D; Sfacteria A; Grasso G
    World Neurosurg; 2019 Nov; 131():346-355. PubMed ID: 31658577
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Epo-induced hemoglobinization of SKT6 cells is mediated by minimal cytoplasmic domains of the Epo or prolactin receptors without modulation of GATA-1 or EKLF.
    Reese TT; Gregory RC; Sharlow ER; Pacifici RE; Crouse JA; Todokoro K; Wojchowski DM
    Growth Factors; 1997; 14(2-3):161-76. PubMed ID: 9255607
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The human erythropoietin receptor.
    Winkelmann JC
    Int J Cell Cloning; 1992 Sep; 10(5):254-61. PubMed ID: 1453011
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma.
    Lai SY; Childs EE; Xi S; Coppelli FM; Gooding WE; Wells A; Ferris RL; Grandis JR
    Oncogene; 2005 Jun; 24(27):4442-9. PubMed ID: 15856028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.